{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:04:15Z","timestamp":1788375855647,"version":"build-2803163510"},"reference-count":33,"publisher":"The Journal of Rheumatology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the efficacy and safety of celecoxib and naproxen in children with juvenile rheumatoid arthritis (JRA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this multicenter, randomized, double-blind, noninferiority study, subjects with JRA were randomized to receive a target dose of celecoxib 3 mg\/kg bid or 6 mg\/kg bid, or a target dose of naproxen 7.5 mg\/kg bid for 12 weeks (maximum allowed dose = 600 mg total daily dose). The primary efficacy measure was the percentage of responders at Week 12 attaining the American College of Rheumatology pediatric 30% improvement criterion (ACR Pediatric-30).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Both celecoxib doses were at least as effective as naproxen at Week 12 [ACR Pediatric-30 treatment differences: celecoxib 3 mg\/kg bid \u2013 naproxen = 1.36% (95% CI \u201313.08 to 15.80); celecoxib 6 mg\/kg bid \u2013 naproxen = 13.02% (95% CI \u20130.22 to 26.25)]. Celecoxib 6 mg\/kg bid had a numerically higher response rate than celecoxib 3 mg\/kg bid at all postrandomization visits and a numerically higher response rate than naproxen 7.5 mg\/kg bid at Weeks 4, 8, and 12. Improvement in each ACR Pediatric-30 core set measure was comparable to or numerically higher for celecoxib 6 mg\/kg bid than naproxen or celecoxib 3 mg\/kg bid. Adverse event rates were similar for all treatment groups, except that gastrointestinal adverse events were more common in the naproxen group, although the difference was not statistically significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Celecoxib 3 mg\/kg bid and 6 mg\/kg bid were at least as effective as naproxen 7.5 mg\/kg bid in treating the signs and symptoms of JRA over 12 weeks. All treatments were generally well tolerated.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.080073","type":"journal-article","created":{"date-parts":[[2008,11,14]],"date-time":"2008-11-14T12:12:38Z","timestamp":1226664758000},"page":"174-182","source":"Crossref","is-referenced-by-count":57,"title":["A Prospective Study Comparing Celecoxib with Naproxen in Children with Juvenile Rheumatoid Arthritis"],"prefix":"10.3899","volume":"36","author":[{"given":"IVAN","family":"FOELDVARI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ILONA S.","family":"SZER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LAWRENCE S.","family":"ZEMEL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DANIEL J.","family":"LOVELL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EDWARD H.","family":"GIANNINI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JEFFERY L.","family":"ROBBINS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHRISTINE R.","family":"WEST","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GINA","family":"STEIDLE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SRIRAM","family":"KRISHNASWAMI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BRADLEY J.","family":"BLOOM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2009,1,1]]},"reference":[{"key":"2018112909180224000_36.1.174.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.3.245"},{"key":"2018112909180224000_36.1.174.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10986"},{"key":"2018112909180224000_36.1.174.3","first-page":"2036","article-title":"Current treatment by United States and Canadian pediatric rheumatologists","volume":"26","author":"Cron","year":"1999","journal-title":"J Rheumatol"},{"key":"2018112909180224000_36.1.174.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.20860"},{"key":"2018112909180224000_36.1.174.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209103271101"},{"key":"2018112909180224000_36.1.174.6","doi-asserted-by":"publisher","DOI":"10.1186\/ar1704"},{"key":"2018112909180224000_36.1.174.7","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958050-00006"},{"key":"2018112909180224000_36.1.174.8","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R"},{"key":"2018112909180224000_36.1.174.9","first-page":"985","article-title":"Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension","volume":"33","author":"Reiff","year":"2006","journal-title":"J Rheumatol"},{"key":"2018112909180224000_36.1.174.10","unstructured":"Gedalia A Espada G Johnson P Kovacs B Wood C Padula S Meloxicam in JRA Study Group . Efficacy and safety of meloxicam oral suspension in the treatment of juvenile rheumatoid arthritis (JRA): results from a twelve-week active-controlled (naproxen oral suspension), multinational trial [abstract]. Arthritis Rheum 2004;50 Suppl:S95."},{"key":"2018112909180224000_36.1.174.11","first-page":"381","article-title":"A six-month open safety assessment of a naproxen suspension formulation in the therapy of juvenile rheumatoid arthritis","volume":"10","author":"Laxer","year":"1988","journal-title":"Clin Ther"},{"key":"2018112909180224000_36.1.174.12","doi-asserted-by":"crossref","unstructured":"National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents . The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114 Suppl 2:1\u201322.","DOI":"10.1542\/peds.114.2.S2.555"},{"key":"2018112909180224000_36.1.174.13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3109\/03009748409111307","article-title":"Naproxen and acetylsalicylic acid in the treatment of pauciarticular and polyarticular juvenile rheumatoid arthriti. Assessment of tolerance and efficacy in a single-centre 24-week double-blind parallel study","volume":"13","author":"Kvien","year":"1984","journal-title":"Scand J Rheumatol"},{"key":"2018112909180224000_36.1.174.14","first-page":"157","article-title":"A crossover study of naproxen, diclofenac and tolmetin in seronegative juvenile chronic arthritis","volume":"6","author":"Leak","year":"1988","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909180224000_36.1.174.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)80708-5"},{"key":"2018112909180224000_36.1.174.16","first-page":"829","article-title":"An open label study to establish dosing recommendations for nabumetone in juvenile rheumatoid arthritis","volume":"30","author":"Goodman","year":"2003","journal-title":"J Rheumatol"},{"key":"2018112909180224000_36.1.174.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(77)81045-7"},{"key":"2018112909180224000_36.1.174.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.38.2.152"},{"key":"2018112909180224000_36.1.174.19","first-page":"1081","article-title":"Flurbiprofen in the treatment of juvenile rheumatoid arthritis","volume":"13","author":"Bass","year":"1986","journal-title":"J Rheumatol"},{"key":"2018112909180224000_36.1.174.20","first-page":"384","article-title":"A once-daily antiinflammatory drug, oxaprozin, in the treatment of juvenile rheumatoid arthritis. The Pediatric Rheumatology Collaborative Study Group","volume":"12","author":"Bass","year":"1985","journal-title":"J Rheumatol"},{"key":"2018112909180224000_36.1.174.21","first-page":"276","article-title":"Double-blind study of ketoprofen and indomethacin in juvenile chronic arthritis","volume":"54","author":"Bhettay","year":"1978","journal-title":"S Afr Med J"},{"key":"2018112909180224000_36.1.174.22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/03009748309099735","article-title":"Treatment of juvenile rheumatoid arthritis with diclofenac sodium","volume":"12","author":"Haapasaari","year":"1983","journal-title":"Scand J Rheumatol"},{"key":"2018112909180224000_36.1.174.23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/25.1.67"},{"key":"2018112909180224000_36.1.174.24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.rhu.0000152151.12999.76","article-title":"Pediatric rheumatology for the adult rheumatologist. I: Therapy and dosing for pediatric rheumatic disorders","volume":"11","author":"DeWitt","year":"2005","journal-title":"J Clin Rheumatol"},{"key":"2018112909180224000_36.1.174.25","first-page":"1149","article-title":"Clinically significant gastropathy associated with nonsteroidal antiinflammatory drug use in children with juvenile rheumatoid arthritis","volume":"22","author":"Keenan","year":"1995","journal-title":"J Rheumatol"},{"key":"2018112909180224000_36.1.174.26","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0022-3476(05)83556-5","article-title":"Identification of nonsteroidal antiinflammatory drug-induced gastroduodenal injury in children with juvenile rheumatoid arthritis","volume":"122","author":"Mulberg","year":"1993","journal-title":"J Pediatr"},{"key":"2018112909180224000_36.1.174.27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/32.1.69"},{"key":"2018112909180224000_36.1.174.28","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/art.1780380908","article-title":"Nonsteroidal antiinflammatory drug-induced gastroduodenal injury in children","volume":"38","author":"Dowd","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2018112909180224000_36.1.174.29","first-page":"S141","article-title":"Gastroduodenal adverse reactions to drugs in children in Italy [abstract]","volume":"13","author":"Menniti-Ippolito","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2018112909180224000_36.1.174.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061355"},{"key":"2018112909180224000_36.1.174.31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.17.2107"},{"key":"2018112909180224000_36.1.174.32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.502161"},{"key":"2018112909180224000_36.1.174.33","unstructured":"Cassidy JT Petty RE . Textbook of pediatric rheumatology. 5th ed. Philadelphia: W.B. Saunders; 2005."}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.080073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T09:01:48Z","timestamp":1557910908000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.080073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.3899\/jrheum.080073"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.080073","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}